A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation

Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects

(2016) Takayuki Katsube et al.   CLINICAL PHARMACOKINETICS

Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs

(2015) Daiming Fan et al.   THROMBOSIS AND HAEMOSTASIS

Management of thrombocytopenia due to liver cirrhosis: A review

(2014) Hiromitsu Hayashi   WORLD JOURNAL OF GASTROENTEROLOGY

Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia

(2012) Nezam H. Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention

(2009) E. C. Vamvakas et al.   BLOOD

Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development

(2009) Maria Assunta Zocco et al.   JOURNAL OF HEPATOLOGY

Thrombocytopenia associated with chronic liver disease

(2008) Nezam Afdhal et al.   JOURNAL OF HEPATOLOGY